# CareCloud, Inc.: Form 10-Q for the period ended Sep 30, 2021

- Company: [CareCloud, Inc.](/companies/ccld.md) (CIK 1582982)
- Form: 10-Q
- Filed: 2021-11-04
- Accepted by EDGAR: Nov 4, 2021, 16:49 ET
- Period: 2021-09-30
- Accession: 0001493152-21-027262
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1582982/000149315221027262/form10-q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1582982/000149315221027262/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-07-01 to 2021-09-30 | $38.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2021-01-01 to 2021-09-30 | $102.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months, 2021-07-01 to 2021-09-30 | $488.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2021-01-01 to 2021-09-30 | $4.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2021-07-01 to 2021-09-30 | $1.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2021-01-01 to 2021-09-30 | −$362.0k | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2021-07-01 to 2021-09-30 | −$232.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2021-01-01 to 2021-09-30 | −$20.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2021-07-01 to 2021-09-30 | $1.5m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2021-01-01 to 2021-09-30 | −$686.0k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-07-01 to 2021-09-30 | −$0.15 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2021-01-01 to 2021-09-30 | −$0.77 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2021-01-01 to 2021-09-30 | $7.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2021-01-01 to 2021-09-30 | $2.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Shareholders' equity | at 2021-09-30 | $97.1m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 53,576 characters.

The following is a discussion of our condensed consolidated financial condition and results of operations for the three and nine months ended September 30, 2021 and 2020, and other factors that are expected to affect our prospective financial condition. The following discussion and analysis should be read together with our Condensed Consolidated Financial Statements and related notes beginning on page 4 of this Quarterly Report on Form 10-Q.

Some of the statements set forth in this section are forward-looking statements relating to our future results of operations. Our actual results may vary from the results anticipated by these statements. Please see “*Forward-Looking Statements”* on page 2 of this Quarterly Report on Form 10-Q.

### COVID-19 Pandemic

In December 2019, a novel strain of coronavirus, SARS-CoV-2, was reported to have surfaced in Wuhan, China. Since then, SARS-CoV-2, and the resulting disease COVID-19, has spread to most countries, and all 50 states within the United States. In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. Further, the former President of the United States declared the COVID-19 pandemic a national emergency, invoking powers under the Stafford Act, the legislation that directs federal emergency disaster response, and under the Defense Production Act, the legislation that facilitates the production of goods and services necessary for national security and for other purposes. Numerous governmental jurisdictions, including the State of New Jersey where we maintain our principal executive offices, and those in which many of our U.S. and international offices are based, have imposed, and others in the future may impose, “shelter-in-place” orders, quarantines, executive orders and similar government orders and restrictions for their residents to control the spread of COVID-19. Most states and the federal government, including the State of New Jersey, together with foreign jurisdictions in which we have operations centers, had declared a state of emergency related to the spread of COVID-19.

While the COVID-19 pandemic did not materially adversely affect the Company’s consolidated financial results and operations during the nine months ended September 30, 2021, economic and health conditions in the United States and across most of the globe continue to change. The Company expanded its telehealth operations, which is an alternative to office visits. However, not all physicians are using telehealth and not to the same extent as previous office visits.

The COVID-19 pandemic is affecting the Company’s operations in 2021, and may continue to do so indefinitely thereafter. The pandemic may have an impact on the Company’s business, operations, and financial results and conditions, directly and indirectly, including, without limitation, impacts on the health of the Company’s management and employees, its operations, marketing and sales activities, and on the overall economy. The spread of the virus did not adversely affect the health and availability of our employees and staff. The scope and nature of these impacts, most of which are beyond the Company’s control, continue to evolve and the outcomes are uncertain.

Due to the above circumstances and as described generally in this Quarterly Report on Form 10-Q, the Company’s consolidated results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the full fiscal year. The Company is not aware of any certain event or circumstance that would require an update to its estimates or judgements or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. These estimates could change in the future as new information about future developments is obtained. Management cannot predict the full impact of the COVID-19 pandemic on the Company’s consolidated operations nor on economic conditions generally, including the effects on patient visits. The ultimate extent of the effects of the COVID-19 pandemic on the Company is highly uncertain and will depend on highly unpredictable factors such as the ultimate geographic spread of the disease, the severity of the disease, the duration of outbreak, and the effectiveness of any further developments globally and nationally. The Company will actively monitor the situation and take further action that is in the best interest of our employees, customers, partners, and stockholders.

### Overview

CareCloud, Inc. (“CareCloud” and together with its consolidated subsidiaries, the “Company,” “we,” “us” and/or “our”) is a healthcare information technology company that provides a full suite of proprietary cloud-based solutions, together with related business services, to healthcare providers and hospitals throughout the United States. Our Software-as-a-Service (“SaaS”) platform includes revenue cycle management (“RCM”), practice management (“PM”), electronic health record (“EHR”), business intelligence, telehealth, patient experience management (“PXM”) solutions and complementary software tools and business services for high-performance medical groups and health systems.

At a high level, these solutions can be categorized as follows:

- Technology-enabled business solutions, which are often bundled but are occasionally provided individually, including:
- EHRs, which are easy to use, integrated with our business services or offered as Software-as-a-Service (“SaaS”) solutions, and allow our healthcare provider clients to deliver better patient care, document their clinical visits effectively and thus potentially qualify for government incentives, reduce documentation errors and reduce paperwork;
- PM software and related tools, which support our clients’ day-to-day business operations and workflows;
- Mobile Health (“mHealth”) solutions, including smartphone applications that assist patients and healthcare providers in the provision of healthcare services;
- Telehealth solutions, which allow healthcare providers to conduct remote patient visits;
- Healthcare claims clearinghouse, which enables our clients to electronically scrub and submit claims to, and process payments from, insurance companies;
- Business intelligence, customized applications, interfaces and a variety of other technology solutions that support our healthcare clients; and
- RCM services, which include end-to-end medical billing, eligibility, analytics, and related services, all of which can often be provided either with our technology platform or through a third-party system.
- Professional services consisting of application and advisory services, revenue cycle services, data analytic services and educational training services.
- Medical practice management services are provided to medical practices. In this service model, we provide the medical practice with appropriate facilities, equipment, supplies, support services, nurses and administrative support staff. We also provide management, bill-paying and financial advisory services.

Our solutions enable clients to increase financial and operational performance, streamline clinical workflows, get better insight through data, and make better business and clinical decisions, resulting in improvement in patient care and collections while reducing administrative burdens and operating costs.

The modernization of the healthcare industry is transforming nearly every aspect of a healthcare organization from policy to providers, clinical care to member services, devices to data, and ultimately the quality of the patient’s experience as a healthcare consumer. We create elegant, user-friendly applications that solve many of the challenges facing healthcare organizations. We partner with organizations to develop customized, best-in-class solutions to solve their specific challenges while ensuring they also meet future regulatory and organizational requirements and market demands.

We are able to deliver our industry-leading solutions at very competitive prices because we leverage a combination of our proprietary software, which automates our workflows and increases efficiency, together with our team of approximately 700 experienced health industry experts throughout the United States. These experts are supported by our highly educated and specialized offshore workforce of approximately 3,400 team members at labor costs that we believe are approximately one-tenth the cost of comparable U.S. employees. Our unique business model also allowed us to become a leading consolidator in our industry sector, gaining us a reputation for acquiring and positively transforming distressed competitors into profitable operations of CareCloud.

Adoption of our technology-enabled business solutions typically requires little or no upfront expenditure by a client. Additionally, for most of our solutions and customers, our financial performance is linked directly to the financial performance of our clients, as the vast majority of our revenues are based on a percentage of our clients’ collections. The fees we charge for our complete, integrated, end-to-end solution are very competitive and among the lowest in the industry. We estimate that we currently provide services to more than 40,000 providers, (which we define as physicians, nurses, nurse practitioners, physician assistants and other clinical staff that render bills for their services) practicing in approximately 2,600 independent medical practices and hospitals representing 80 specialties and subspecialties in 50 states. In addition, we serve approximately 200 clients that are not medical practices, but are primarily service organizations who serve the healthcare community. The foregoing numbers include clients leveraging any of our products or services, and are based, in part, upon estimates where the precise number of practices or providers is unknown.

We service clients ranging from small practices, consisting of one to ten providers, to large practices with over 2,300 providers operating in multiple states, to community hospitals.

On January 8, 2020, through a merger with a subsidiary, the Company acquired CareCloud Corporation, a Delaware corporation which was subsequently renamed CareCloud Health, Inc. (“CCH”), which has developed a highly acclaimed cloud-based platform including EHR, PM and patient experience capabilities. The Company paid $11.9 million in cash, assumed a working capital deficiency of approximately $5.1 million and issued 760,000 shares of the Company’s Series A Preferred Stock and two million warrants for the purchase of the Company’s common stock at prices of $7.50 for two years and $10.00 per share for three years.

On June 16, 2020, the Company purchased all of the issued and outstanding capital stock of Meridian Billing Management Co. and its affiliate Origin Holdings, Inc. (collectively, “Meridian,” and sometimes referred to as “Meridian Medical Management”), a former GE Healthcare IT company that delivers advanced healthcare information technology solutions and services. The Company paid $11.9 million in cash, issued 200,000 shares of the Company’s Series A Preferred Stock and warrants to purchase 2,250,000 of the Company’s common stock with an exercise price per share of $7.50 for two years and assumed Meridian’s negative working capital and certain long-term lease liabilities where the space is either not being utilized or will be vacated shortly, with an aggregate value of approximately $4.8 million.

On June 1, 2021, CareCloud Acquisition Corp (“CAC”), a wholly-owned subsidiary, entered into an Asset and Stock Purchase Agreement (the “Purchase Agreement”) with MedMatica Consulting Associates, Inc., (“MedMatica”) whereby CAC purchased the assets of MedMatica and the stock of its wholly-owned subsidiary Santa Rosa Staffing, Inc. (“SRS”). MedMatica and SRS provide a broad range of specialty consulting services to hospitals and large healthcare groups, including certain consulting services related to healthcare IT applications services and implementations, practice management, and revenue cycle management. The total consideration paid at closing was $10 million in cash, net of $1.5 million of escrow withheld. A working capital adjustment of approximately $3.8 million was also paid at closing. The Purchase Agreement provides that if during the 18-month period commencing on June 1, 2021 (“the “Earn-Out Period”), CAC’s EBITDA and revenue targets are achieved, then CAC shall pay an earn-out up to a maximum of $8 million (the “Base Earn-Out”). If during the Earn-Out Period, CAC’s additional and increased EBITDA and revenue targets are achieved, then CAC shall pay an additional earn-out, up to a maximum of $5 million (the “Additional Earn-Out”, collectively, with the Base Earn-Out, the “Earn-Out”). CAC will have the right to offset the Earn-Out against any claim for which CAC is entitled to indemnification under the Purchase Agreement and against damages for breaches by the seller of the non-competition and non-solicitation provisions in the Purchase Agreement.

Our offshore operations in the Pakistan Offices and Sri Lanka accounted for approximately 11% and 10% of total expenses for the nine months ended September 30, 2021 and 2020, respectively. A significant portion of those foreign expenses were personnel-related costs (approximately 80% for both the nine months ended September 30, 2021 and 2020). Because personnel-related costs are significantly lower in Pakistan and Sri Lanka than in the U.S. and many other offshore locations, we believe our offshore operations give us a competitive advantage over many industry participants. We are able to achieve significant cost reductions and leverage technology to reduce manual work and strategically transition a portion of the remaining manual tasks to our highly-specialized, cost-efficient team in the U.S., the Pakistan Offices and Sri Lanka.

### Key Performance Measures

We consider numerous factors in assessing our performance. Key performance measures used by management, including adjusted EBITDA, adjusted operating income, adjusted operating margin, adjusted net income and adjusted net income per share, are non-GAAP financial measures, which we believe better enable management and investors to analyze and compare the underlying business results from period to period.

These non-GAAP financial measures should not be considered in isolation, or as a substitute for or superior to, financial measures calculated in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Moreover, these non-GAAP financial measures have limitations in that they do not reflect all the items associated with the operations of our business as determined in accordance with GAAP. We compensate for these limitations by analyzing current and future results on a GAAP basis as well as a non-GAAP basis, and we provide reconciliations from the most directly comparable GAAP financial measures to the non-GAAP financial measures. Our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate similarly titled non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

Adjusted EBITDA, adjusted operating income, adjusted operating margin, adjusted net income and adjusted net income per share provide an alternative view of performance used by management and we believe that an investor’s understanding of our performance is enhanced by disclosing these adjusted performance measures.

Adjusted EBITDA excludes the following elements which are included in GAAP net income (loss):

- Income tax expense (benefit) or the cash requirements to pay our taxes;
- Interest expense, or the cash requirements necessary to service interest on principal payments, on our debt;
- Foreign currency gains and losses and other non-operating expenditures;
- Stock-based compensation expense includes cash-settled awards and the related taxes, based on changes in the stock price;
- Depreciation and amortization charges;
- Integration costs, such as severance amounts paid to employees from acquired businesses, and transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees and exit costs related to contractual agreements; and
- Loss on lease termination, impairment and unoccupied lease charges.

Set forth below is a presentation of our adjusted EBITDA for the three and nine months ended September 30, 2021 and 2020:

*($ in thousands)*

|  | Three Months Ended September 30, 2021 | 2020 | Nine Months Ended September 30, 2021 | 2020 |
| --- | ---: | ---: | ---: | ---: |
| Net revenue | $38,304 | $31,639 | $102,137 | $73,085 |
| GAAP net income (loss) | 1,505 | (1,673) | (686) | (8,968) |
| (Benefit) provision for income taxes | (232) | 62 | (20) | 18 |
| Net interest expense | 87 | 130 | 264 | 352 |
| Foreign exchange loss / other expense | 70 | 296 | 167 | (17) |
| Stock-based compensation expense | 1,004 | 1,763 | 4,006 | 4,951 |
| Depreciation and amortization | 3,547 | 3,206 | 9,505 | 6,944 |
| Transaction and integration costs | 269 | 609 | 1,118 | 1,709 |
| Loss on lease termination, impairment and unoccupied lease charges | 424 | 321 | 1,664 | 681 |
| Change in contingent consideration | - | (500) | - | (500) |
| Adjusted EBITDA | **$6,674** | **$4,214** | **$16,018** | **$5,170** |

31

Adjusted operating income and adjusted operating margin exclude the following elements that are included in GAAP operating income (loss):

- Stock-based compensation expense includes cash-settled awards and the related taxes, based on changes in the stock price;
- Amortization of purchased intangible assets;
- Integration costs, such as severance amounts paid to employees from acquired businesses, and transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees and exit costs related to contractual agreements; and
- Loss on lease termination, impairment and unoccupied lease charges.

Set forth below is a presentation of our adjusted operating income and adjusted operating margin, which represents adjusted operating income as a percentage of net revenue, for the three and nine months ended September 30, 2021 and 2020:

*($ in thousands)*

|  | Three Months Ended September 30, 2021 | 2020 | Nine Months Ended September 30, 2021 | 2020 |
| --- | ---: | ---: | ---: | ---: |
| Net revenue | $38,304 | $31,639 | $102,137 | $73,085 |
| GAAP net income (loss) | 1,505 | (1,673) | (686) | (8,968) |
| (Benefit) provision for income taxes | (232) | 62 | (20) | 18 |
| Net interest expense | 87 | 130 | 264 | 352 |
| Other expense (income) - net | 65 | 246 | 80 | (84) |
| GAAP operating income (loss) | 1,425 | (1,235) | (362) | (8,682) |
| GAAP operating margin | 3.7% | (3.9)% | (0.4)% | (11.9)% |
| Stock-based compensation expense | 1,004 | 1,763 | 4,006 | 4,951 |
| Amortization of purchased intangible assets | 2,768 | 2,690 | 7,079 | 5,751 |
| Transaction and integration costs | 269 | 609 | 1,118 | 1,709 |
| Loss on lease termination, impairment and unoccupied lease charges | 424 | 321 | 1,664 | 681 |
| Change in contingent consideration | - | (500) | - | (500) |
| Non-GAAP adjusted operating income | **$5,890** | **$3,648** | **$13,505** | **$3,910** |
| Non-GAAP adjusted operating margin | 15.4% | 11.5% | 13.2% | 5.3% |

Adjusted net income and adjusted net income per share exclude the following elements which are included in GAAP net income (loss):

- Foreign currency gains and losses and other non-operating expenditures;
- Stock-based compensation expense includes cash-settled awards and the related taxes, based on changes in the stock price;
- Amortization of purchased intangible assets;
- Integration costs, such as severance amounts paid to employees from acquired businesses, and transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees and exit costs related to contractual agreements;
- Loss on lease termination, impairment and unoccupied lease charges; and
- Income tax expense (benefit) resulting from the amortization of goodwill related to our acquisitions.

32

No tax effect has been provided in computing non-GAAP adjusted net income and non-GAAP adjusted net income per share as the Company has sufficient carry forward net operating losses to offset the applicable income taxes. The following table shows our reconciliation of GAAP net loss to non-GAAP adjusted net income for the three and nine months ended September 30, 2021 and 2020:

*($ in thousands)*

|  | Three Months Ended September 30, 2021 | 2020 | Nine Months Ended September 30, 2021 | 2020 |
| --- | ---: | ---: | ---: | ---: |
| GAAP net income (loss) | $1,505 | $(1,673) | $(686) | $(8,968) |
| Foreign exchange loss / other expense | 70 | 296 | 167 | (17) |
| Stock-based compensation expense | 1,004 | 1,763 | 4,006 | 4,951 |
| Amortization of purchased intangible assets | 2,768 | 2,690 | 7,079 | 5,751 |
| Transaction and integration costs | 269 | 609 | 1,118 | 1,709 |
| Loss on lease termination, impairment and unoccupied lease charges | 424 | 321 | 1,664 | 681 |
| Change in contingent consideration | - | (500) | - | (500) |
| Income tax expense (benefit) related to goodwill | 13 | 7 | 140 | (93) |
| Non-GAAP adjusted net income | **$6,053** | **$3,513** | **$13,488** | **$3,514** |

Set forth below is a reconciliation of our GAAP net loss attributable to common shareholders, per share to our non-GAAP adjusted net income per share:

|  | Three Months Ended September 30, 2021 | 2020 | Nine Months Ended September 30, 2021 | 2020 |
| --- | ---: | ---: | ---: | ---: |
| GAAP net loss attributable to common shareholders, per share | $(0.15) | $(0.46) | $(0.77) | $(1.53) |
| Impact of preferred stock dividend | 0.25 | 0.33 | 0.72 | 0.85 |
| Net income (loss) per end-of-period share | 0.10 | (0.13) | (0.05) | (0.68) |
| Foreign exchange loss / other expense | 0.00 | 0.02 | 0.01 | 0.00 |
| Stock-based compensation expense | 0.07 | 0.14 | 0.27 | 0.38 |
| Amortization of purchased intangible assets | 0.19 | 0.20 | 0.48 | 0.44 |
| Transaction and integration costs | 0.02 | 0.06 | 0.08 | 0.13 |
| Loss on lease termination, impairment and unoccupied lease charges | 0.03 | 0.02 | 0.11 | 0.05 |
| Change in contingent consideration | 0.00 | (0.04) | 0.00 | (0.04) |
| Income tax expense (benefit) related to goodwill | 0.00 | 0.00 | 0.01 | (0.01) |
| Non-GAAP adjusted earnings per share | **$0.41** | **$0.27** | **$0.91** | **$0.27** |
| End-of-period common shares | 14,873,411 | 13,136,088 | 14,873,411 | 13,136,088 |
| In-the-money warrants and outstanding unvested RSUs | 2,432,636 | 4,910,423 | 2,432,636 | 4,910,423 |
| Total fully diluted shares | 17,306,047 | 18,046,511 | 17,306,047 | 18,046,511 |
| Non-GAAP adjusted diluted earnings per share | **$0.35** | **$0.19** | **$0.78** | **$0.19** |

For purposes of determining non-GAAP adjusted earnings per share, the Company used the number of common shares outstanding at the end of September 30, 2021 and 2020. Non-GAAP adjusted diluted earnings per share was computed using an as-converted method and includes warrants that are in-the-money as of that date as well as outstanding unvested RSUs. Non-GAAP adjusted earnings per share and non-GAAP adjusted diluted earnings per share do not take into account dividends paid on Preferred Stock. No tax effect has been provided in computing non-GAAP adjusted earnings per share and non-GAAP adjusted diluted earnings per share as the Company has sufficient carry forward net operating losses to offset the applicable income taxes.

### Key Metrics

In addition to the line items in our condensed consolidated financial statements, we regularly review the following metrics. We believe information on these metrics is useful for investors to understand the underlying trends in our business.

*Providers and Practices Served:* As of September 30, 2021, we provided services to an estimated universe of more than 40,000 providers (which we define as physicians, nurses, nurse practitioners, physician assistants and other clinical staff that render bills for their services), representing approximately 2,600 independent medical practices and hospitals. In addition, we served approximately 200 clients who were not medical practices, but are service organizations who serve the healthcare community. The foregoing numbers include clients leveraging any of our products or services and are based in part upon estimates in cases where the precise number of practices or providers is unknown.

### Sources of Revenue

*Revenue:* We primarily derive our revenues from subscription-based technology-enabled business solutions, reported in our Healthcare IT segment, which are typically billed as a percentage of payments collected by our customers. This fee includes RCM, as well as the ability to use our EHR, practice management system and other software as part of the bundled fee. These solutions accounted for approximately 71% and 86% of our revenues during the three months ended September 30, 2021 and 2020, respectively, and 78% and 84% for the nine months ended September 30, 2021 and 2020, respectively. Other Healthcare IT services, including printing and mailing operations, group purchasing and professional services, represented approximately 20% and 4% of revenues for the three months ended September 30, 2021 and 2020, respectively, and 13% and 4% for the nine months ended September 30, 2021 and 2020, respectively.

We earned approximately 9% and 11% of our revenue from medical practice management services during the three months ended September 30, 2021 and 2020, respectively, and 9% and 12% for the nine months ended September 30, 2021 and 2020, respectively. This revenue represents fees based on our actual costs plus a percentage of the operating profit and is reported in our Medical Practice Management segment.

### Operating Expenses

*Direct Operating Costs.* Direct operating cost consists primarily of salaries and benefits related to personnel who provide services to our customers, claims processing costs, costs to operate the three managed practices, including facility lease costs, supplies, insurance and other direct costs related to our services. Costs associated with the implementation of new customers are expensed as incurred. The reported amounts of direct operating costs do not include depreciation and amortization, which are broken out separately in the condensed consolidated statements of operations.

*Selling and Marketing Expense.* Selling and marketing expense consists primarily of compensation and benefits, commissions, travel and advertising expenses.

*General and Administrative Expense.* General and administrative expense consists primarily of personnel-related expense for administrative employees, including compensation, benefits, travel, facility lease costs and insurance, software license fees and outside professional fees.

*Research and Development Expense.* Research and development expense consists primarily of personnel-related costs and third-party contractor costs.

*Contingent Consideration.* Contingent consideration represents the portion of consideration payable to the sellers of some of our acquisitions, the amount of which is based on the achievement of defined performance measures contained in the purchase agreements. Contingent consideration is adjusted to fair value at the end of each reporting period.

*Depreciation and Amortization Expense.* Depreciation expense is charged using the straight-line method over the estimated lives of the assets ranging from three to five years. Amortization expense is charged on either an accelerated or on a straight-line basis over a period of three or four years for most intangible assets acquired in connection with acquisitions including those intangibles related to the group purchasing services. Amortization expense related to the value of our medical practice management clients is amortized on a straight-line basis over a period of twelve years.

*Loss on lease termination, Impairment and Unoccupied Lease Charges.* Loss on lease termination represents the write-off of leasehold improvements as the result of an early lease termination. Impairment charges represent charges recorded for a leased facility no longer being used by the Company and a non-cancellable vendor contract where the services are no longer being used. Unoccupied lease charges represent the portion of lease and related costs for vacant space not being utilized by the Company. The Company is marketing both the unused facility and the unused space for sub-lease.

*Interest and Other Income (Expense).* Interest expense consists primarily of interest costs related to our line of credit, term loans and amounts due in connection with acquisitions, offset by interest income. Other income (expense) results primarily from foreign currency transaction gains (losses) and income earned from temporary cash investments.

*Income Tax.* In preparing our condensed consolidated financial statements, we estimate income taxes in each of the jurisdictions in which we operate. This process involves estimating actual current tax exposure together with assessing temporary differences resulting from differing treatment of items for tax and financial reporting purposes. These differences result in deferred income tax assets and liabilities. Although the Company is forecasting a return to profitability, it incurred losses historically and there is uncertainty regarding future U.S. taxable income, which makes realization of a deferred tax asset difficult to support in accordance with ASC 740. Accordingly, a valuation allowance has been recorded against all deferred tax assets as of September 30, 2021 and December 31, 2020.

### Critical Accounting Policies and Estimates

The critical accounting policies and estimates used in the preparation of our condensed consolidated financial statements that we believe affect our more significant judgments and estimates used in the preparation of our condensed consolidated financial statements presented in this Report are described in Management’s Discussion and Analysis of Financial Condition and Results of Operations and in the Notes to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020.

#### Leases:

We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, operating lease liability (current portion) and operating lease liability (noncurrent portion) in the condensed consolidated balance sheets at September 30, 2021 and December 31, 2020. The Company does not have any finance leases.

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term.

We use our estimated incremental borrowing rates, which are derived from information available at the lease commencement date, in determining the present value of lease payments. We give consideration to bank financing arrangements, geographical location and collateralization of assets when calculating our incremental borrowing rates.

Our lease term includes options to extend the lease when it is reasonably certain that we will exercise that option. Leases with a term of less than 12 months are not recorded in the condensed consolidated balance sheet. Our lease agreements do not contain any residual value guarantees. For real estate leases, we account for the leased and non-leased components as a single lease component. Some leases include escalation clauses and termination options that are factored into the determination of the future lease payments when appropriate.

*Capitalized software costs:*

All of our software is considered internal use for accounting purposes, as we do not market or sell our software. As a result, we capitalize certain costs associated with the creation of internally-developed software for internal use. The total of these costs is recorded in Intangible assets - net in our condensed consolidated balance sheets.

We capitalized costs incurred during the application development stage related to our internal use software. Costs incurred during the application development phase are capitalized only when we believe it is probable that the development will result in new or additional functionality. The types of costs capitalized during the application development phase consist of employee compensation, employee benefits and employee stock- based compensation. Costs related to the preliminary project stage and post-implementation activities are expensed as incurred. Capitalized internal-use software is amortized on a straight-line basis over its estimated useful life when the asset has been placed in service for general availability.

Significant judgments related to internally-developed software include determining whether it is probable that projects will result in new or additional functionality; concluding on when the application development phase starts and ends; and deciding which costs, especially employee compensation costs, should be capitalized. Additionally, there is judgment applied to the useful lives of capitalized software; we have concluded that the useful lives for capitalized internally-developed software is three years.

Company management employs its best estimates and assumptions in determining the appropriateness of the judgments noted above on a project-by-project basis during initial capitalization as well as subsequent measurement. While we believe that our approach to estimates and judgments is reasonable, actual results could differ, and such differences could lead to an increase or decrease in expense.

As of September 30, 2021 and December 31, 2020, the carrying amounts of internally-developed capitalized software was $9.8 million and $5.5 million, respectively. The increase in the capitalized software costs represents the continued investment in proprietary technology.

There have been no material changes in our critical accounting policies and estimates from those described in the Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on February 25, 2021.

### Results of Operations

The following table sets forth our consolidated results of operations as a percentage of total revenue for the periods shown:

|  | Three Months Ended September 30, 2021 | 2020 | Nine Months Ended September 30, 2021 | 2020 |
| --- | ---: | ---: | ---: | ---: |
| Net revenue | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating expenses: |  |  |  |  |
| Direct operating costs | 63.0% | 62.3% | 61.4% | 62.7% |
| Selling and marketing | 6.2% | 5.0% | 6.3% | 6.5% |
| General and administrative | 15.5% | 19.6% | 17.4% | 23.5% |
| Research and development | 1.3% | 7.5% | 4.2% | 9.4% |
| Change in contingent consideration | 0.0% | (1.6)% | 0.0% | (0.7)% |
| Depreciation and amortization | 9.3% | 10.1% | 9.3% | 9.5% |
| Loss on lease termination, impairment and unoccupied lease charges | 1.1% | 1.0% | 1.6% | 0.9% |
| Total operating expenses | 96.4% | 103.9% | 100.2% | 111.8% |
| Operating income (loss) | 3.6% | (3.9)% | (0.2)% | (11.8)% |
| Interest expense - net | 0.2% | 0.4% | 0.3% | 0.5% |
| Other (expense) income - net | (0.2)% | (0.8)% | (0.1)% | 0.1% |
| Income (loss) before income taxes | 3.2% | (5.1)% | (0.6)% | (12.2)% |
| Income tax (benefit) provision | (0.6)% | 0.2% | (0.0)% | 0.0% |
| Net income (loss) | 3.8% | (5.3)% | (0.6)% | (12.2)% |

36

### Comparison of the three and nine months ended September 30, 2021 and 2020

*($ in thousands)*

|  | Three Months Ended September 30, 2021 | 2020 | Change Amount | Percent | Nine Months Ended September 30, 2021 | 2020 | Change Amount | Percent |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net revenue | $38,304 | $31,639 | $6,665 | 21% | $102,137 | $73,085 | $29,052 | 40% |

*Net Revenue.* Net revenue of $38.3 million and $102.1 million for the three and nine months ended September 30, 2021, respectively, increased by $6.7 million or 21% and $29.1 million or approximately 40% from net revenue of $31.6 million and $73.1 million for the three and nine months ended September 30, 2020. Revenue for the three and nine months ended September 30, 2021 includes approximately $24.5 million and $63.1 million from customers acquired in the medSR, CCH and Meridian acquisitions. Revenue for the three and nine months ended September 30, 2021 includes $27.1 million and $80.1 million relating to technology-enabled business solutions, $6.9 million and $11.0 million related to professional services and $3.6 million and $9.3 million for medical practice management services.

*($ in thousands)*

|  | Three Months Ended September 30, 2021 | 2020 | Change Amount | Percent | Nine Months Ended September 30, 2021 | 2020 | Change Amount | Percent |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Direct operating costs | $24,124 | $19,718 | $4,406 | 22% | $62,719 | $45,842 | $16,877 | 37% |
| Selling and marketing | 2,375 | 1,571 | 804 | 51% | 6,469 | 4,778 | 1,691 | 35% |
| General and administrative | 5,921 | 6,191 | (270) | (4)% | 17,814 | 17,176 | 638 | 4% |
| Research and development | 488 | 2,367 | (1,879) | (79)% | 4,328 | 6,846 | (2,518) | (37)% |
| Change in contingent consideration | - | (500) | 500 | 100% | - | (500) | 500 | 100% |
| Depreciation | 488 | 382 | 106 | 28% | 1,482 | 944 | 538 | 57% |
| Amortization | 3,059 | 2,824 | 235 | 8% | 8,023 | 6,000 | 2,023 | 34% |
| Loss on lease termination, impairment and unoccupied lease charges | 424 | 321 | 103 | 32% | 1,664 | 681 | 983 | 144% |
| Total operating expenses | $36,879 | $32,874 | $4,005 | 12% | $102,499 | $81,767 | $20,732 | 25% |

*Direct Operating Costs.* Direct operating costs of $24.1 million and $62.7 million for the three and nine months ended September 30, 2021 increased by $4.4 million or 22% and $16.9 million or 37% compared to direct operating costs of $19.7 million and $45.8 million for the three and nine months ended September 30, 2020. During the three and nine months ended September 30, 2021, salary costs increased by $3.1 million and $11.4 million, and outsourcing and processing costs increased by $1.5 million and $5.0 million, respectively. The increase in the costs for the three and nine months ended September 30, 2021 were primarily related to the Meridian and medSR acquisitions.

*Selling and Marketing Expense.* Selling and marketing expense of $2.4 million and $6.5 million for the three and nine months ended September 30, 2021 increased by $804,000 or 51% and $1.7 million or 35% from selling and marketing expense of $1.6 million and $4.8 million for the three and nine months ended September 30, 2020. The increase was primarily related to additional emphasis on sales and marketing activities, including activities as a result of the medSR acquisition.

*General and Administrative Expense.* General and administrative expense of $5.9 million and $17.8 million for the three and nine months ended September 30, 2021 decreased by $270,000 or 4% compared to three months ended September 30, 2020 and increased $638,000 or 4% compared to the nine months ended September 30, 2020. The nine-month increase in general and administrative expense was primarily related to the Meridian and medSR acquisitions.

*Research and Development Expense.* Research and development expense of $488,000 and $4.3 million for the three and nine months ended September 30, 2021 decreased by $1.9 million and $2.5 million from research and development expense of $2.4 million and $6.8 million for the three and nine months ended September 30, 2020. The decrease represents less maintenance work on platforms generating revenue and more resources dedicated to development of new technology which is not yet in commercial use. During the three and nine months ended September 30, 2021, the Company capitalized approximately $2.0 million and $5.3 million of development costs in connection with its internal-use software, respectively.

*Depreciation.* Depreciation of $488,000 and $1.5 million for the three and nine months ended September 30, 2021 increased by $106,000 or 28% and $538,000 or 57% from the depreciation of $382,000 and $944,000 for the three and nine months ended September 30, 2020, primarily due to the property and equipment acquired as part of the Meridian and medSR acquisitions.

*Amortization Expense.* Amortization expense of $3.1 million and $8.0 million for the three and nine months ended September 30, 2021, respectively, increased by $235,000 or 8% and $2.0 million or 34% from amortization expense of $2.8 million and $6.0 million for the three and nine months ended September 30, 2020. The increase was primarily related to the intangible assets acquired from the Meridian and medSR acquisitions.

*Loss on lease termination, Impairment and Unoccupied Lease Charges.* Loss on lease termination of $204,000 represents the write-off of leasehold improvements as the result of early lease terminations. Impairment charges of $774,000 represent charges recorded for a leased facility no longer being used by the Company and the impairment of a vendor contract assumed in the CCH acquisition where the provided services are no longer being used by the Company. Unoccupied lease charges of $686,000 represent the portion of lease and related costs for space not being utilized by the Company. The Company is marketing both the unused facility and the unused space for sub-lease.

*($ in thousands)*

|  | Three Months Ended September 30, 2021 | 2020 | Change Amount | Percent | Nine Months Ended September 30, 2021 | 2020 | Change Amount | Percent |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Interest income | $4 | $2 | $2 | 100% | $10 | $44 | $(34) | (77)% |
| Interest expense | (91) | (132) | 41 | 31% | (274) | (396) | 122 | 31% |
| Other (expense) income - net | (65) | (246) | 181 | 74% | (80) | 84 | (164) | (195)% |
| Income tax (benefit) expense | (232) | 62 | 294 | 474% | (20) | 18 | 38 | 211% |

*Interest Income.* Interest income of $4,000 and $10,000 for the three and nine months ended September 30, 2021, respectively, increased by $2,000 from interest income of $2,000 for the three months ended September 30, 2020 and decreased by $34,000 from interest income of $44,000 for the nine months ended September 30, 2020. The interest income represents interest earned on temporary cash investments.

*Interest Expense.* Interest expense of $91,000 and $274,000 for the three and nine months ended September 30, 2021, respectively, decreased by $41,000 or 31% and $122,000 or 31% from interest expense of $132,000 and $396,000 for the three and nine months ended September 30, 2020, respectively. Interest expense includes the amortization of deferred financing costs, which was $107,000 and $144,000 during the nine months ended September 30, 2021 and 2020, respectively.

*Other (Expense) Income - net.* Other (expense) income - net was ($65,000) and ($80,000) for the three and nine months ended September 30, 2021, respectively compared to other (expense) income - net of ($246,000) and $84,000 for the three and nine months ended September 30, 2020, respectively. Other (expense) income primarily represents foreign currency transaction gains and other expense primarily represents foreign currency transaction losses. These transaction gains and losses result from revaluing intercompany accounts whenever the exchange rate varies and are recorded in the condensed consolidated statements of operations.

*Income Tax (Benefit) Provision.* The benefit for income taxes was $232,000 and $20,000 for the three and nine months ended September 30, 2021, respectively, compared to income tax provisions of $62,000 and $18,000 for the three and nine months ended September 30, 2020, respectively. As a result of the Company incurring a tax loss for 2021 and 2020, which has an indefinite life under the current Federal tax rules, the federal deferred tax liability was offset against the federal net operating loss to the extent allowable in 2021 and 2020. The current income tax benefit for the three and nine months ended September 30, 2021 was approximately $245,000 and $160,000 and includes state minimum taxes and foreign income taxes. The Company filed a claim for refund for approximately $285,000 with the Internal Revenue Service which represented a carryback of losses incurred by Meridian prior to its acquisition. The Company has incurred cumulative losses historically and there is uncertainty regarding future U.S. taxable income, which makes realization of a deferred tax losses difficult to support in accordance with ASC 740. Accordingly, a valuation allowance was recorded against all deferred tax assets at September 30, 2021 and December 31, 2020.

### Liquidity and Capital Resources

Borrowings under the SVB facility are based on 200% of repeatable revenue, reduced by an annualized attrition rate as defined in the agreement. As of September 30, 2021, $6.0 million was drawn on the SVB facility which was fully repaid in October 2021.

During the three and nine months ended September 30, 2021, there was positive cash flow from operations of approximately $5.1 million and $7.2 million, respectively. As of September 30, 2021, the Company had approximately $9.3 million in cash of which $1.0 million is restricted, and positive working capital of $9.9 million.

During April and July 2020, the Company sold 1,932,000 shares of its Series A Preferred Stock and received net proceeds of approximately $44.6 million, after issuance expenses. A portion of these proceeds was used to fully repay the line of credit outstanding at March 31 and June 30, 2020.

During the first quarter of 2021, 858,000 warrants for common stock issued to Midcap Funding as part of the consideration for the Meridian acquisition were exercised at an exercise price of $7.50 per warrant. The Company received net proceeds of approximately $6.4 million.

During June 2021, the Company sold 178,092 shares of common stock and received net proceeds of approximately $1.4 million, after issuance expenses. During the three months ended September 30, 2021, the Company sold 136,395 shares of common stock and received net proceeds of approximately $1.2 million after issuance expenses.

During the quarter ended September 30, 2021, the Company received approximately $1.6 million of cash in error. This amount was repaid in October 2021.

The following table summarizes our cash flows for the periods presented:

*($ in thousands)*

|  | Three Months Ended September 30, 2021 | 2020 | Nine Months Ended September 30, 2021 | 2020 | Change Amount | Percent |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Net cash provided by (used in) operating activities | $5,129 | $(449) | $7,210 | $(4,333) | $11,543 | 266% |
| Net cash used in investing activities | (2,852) | (14,739) | (19,851) | (28,772) | 8,921 | 31% |
| Net cash (used in) provided by financing activities | (2,319) | 29,329 | 1,272 | 36,139 | (34,867) | (96)% |
| Effect of exchange rate changes on cash | (147) | 304 | (243) | (188) | (55) | (29)% |
| Net increase (decrease) in cash and restricted cash | $(189) | $14,445 | $(11,612) | $2,846 | $(14,458) | (508)% |

The income before income taxes was $1.3 million for the three months ended September 30, 2021, and the loss before income taxes was $706,000 for the nine months ended September 30, 2021, which included $3.5 million and $9.5 million of non-cash depreciation and amortization, respectively. The loss before income taxes for the three and nine months ended September 30, 2020 was $1.6 million and $9.0 million, respectively, which included $3.2 million and $6.9 million of non-cash depreciation and amortization, respectively.

During 2021, the Company paid approximately $4.2 million in cash to resolve a civil investigation for which one of the businesses it acquired in 2020 has been subject to since July 2018. Of this amount, $4.0 million came from escrowed shares of preferred stock that the Company held that were subsequently cancelled.

### Operating Activities

Cash provided by operating activities was $7.2 million for the nine months ended September 30, 2021 and cash used by operations was $4.3 million during the nine months ended September 30, 2020. During the nine months ended September 30, 2021, approximately $4.2 million of cash from operations was used to settle a pre-existing contingent liability from the CCH acquisition, which resulted in an equivalent reduction in the value of consideration paid. The decrease in the net loss of $8.3 million for the nine months ended September 30, 2021 as compared to the same period in 2020 was accompanied by the following changes in non-cash items: an increase in depreciation and amortization expense of $3.0 million, a decrease in stock-based compensation expense of $945,000, a change in the provision for deferred income taxes of $233,000 and a decrease in interest accretion of $88,000.

The net change in operating assets and liabilities was $9.1 million. Accounts payable, accrued compensation and accrued expenses decreased by $7.0 million for the nine months ended September 30, 2021, which includes the $4.2 million to resolve the previously mentioned investigation related to a 2020 acquisition, compared to a decrease of $8.4 million for the nine months ended September 30, 2020. Accounts receivable increased by $1.4 million for the nine months ended September 30, 2021 compared with an increase of $1.2 million for the nine months ended September 30, 2020. For the nine months ended September 30, 2021 and 2020, the change in the lease liabilities is included in this amount.

### Investing Activities

Capital expenditures were $2.0 million and $1.3 million for the nine months ended September 30, 2021 and 2020, respectively. The capital expenditures for the nine months ended September 30, 2021 and 2020 primarily represented computer equipment purchased and leasehold improvements for the Pakistan Offices. Software development costs of $5.3 million and $3.8 million for the nine months ended September 30, 2021 and 2020, respectively, were capitalized in connection with the development of software for providing technology-enabled business solutions.

### Financing Activities

Net cash provided by financing activities during the nine months ended September 30, 2021 and 2020 was $1.3 million and $36.1 million, respectively. The Company received $6.4 million from the exercise of common stock warrants, $2.5 million from the sale of common stock and $6.0 million net proceeds from the line of credit during the nine months ended September 30, 2021. Cash used in financing activities during the nine months ended September 30, 2021 included $10.8 million of preferred stock dividends, $745,000 of repayments for debt obligations and $2.1 million of tax withholding obligations paid in connection with stock awards issued to employees. Cash used in financing activities for the nine months ended September 30, 2020 included $7.8 million of preferred stock dividends, $430,000 of repayment for debt obligations, a $1.3 million settlement of a contingent obligation and $1.8 million of tax withholding obligations paid in connection with stock awards issued to employees.

### Contractual Obligations and Commitments

We have contractual obligations under our line of credit. We were in compliance with all SVB covenants as of September 30, 2021. We also maintain operating leases for property and certain office equipment. For additional information, see Contractual Obligations and Commitments under Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on February 25, 2021.

### Off-Balance Sheet Arrangements

As of September 30, 2021, and 2020, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special-purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. During 2020, a New Jersey corporation, talkMD Clinicians, PA (“talkMD”), was formed by the wife of the Executive Chairman, who is a licensed physician, to provide telehealth services. talkMD was determined to be a variable interest entity (“VIE”) for financial reporting purposes because the entity will be controlled by the Company. As of September 30, 2021, talkMD had not yet commenced operations. During September 2021, the Company made arrangements to have the income tax returns prepared for talkMD and will advance the funds for the required taxes. The aggregate amount to be advanced is approximately $3,500. We do not engage in off-balance sheet financing arrangements.

## Market risk

As filed, 175 characters.

We are a smaller reporting company as defined by 17 C.F.R. 229.10(f)(1) and are not required to provide information under this item, pursuant to Item 305(e) of Regulation S-K.

## Controls and procedures

As filed, 2,519 characters.

#### Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, based on the 2013 framework and criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”), evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2021 as required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.

Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officer, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Based on the evaluation of our disclosure controls and procedures, as of September 30, 2021, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

#### Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

For the year ended December 31, 2021, the Company will be required to have an attestation by its independent accountants regarding the effectiveness of its internal controls over financial reporting. Additionally, for the year ended December 31, 2021, the Company will become an accelerated filer.

## Risk factors

As filed, 688 characters.

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I—Item 1A. “Risk Factors” in our Annual Report on Form 10-K, filed with the SEC on February 25, 2021, which could materially affect our business, financial condition and/or future results and may be further impacted by the coronavirus pandemic. The risks described in our Annual Report on Form 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, cash flows and/or future results.

Filed Nov 4, 2021.
Source: SEC EDGAR, the filing index for accession 0001493152-21-027262. Last ingested by Listed: Nov 5, 2026, 18:58 ET. No prices; not investment advice.
